Claims for Patent: 5,616,599

Summary for Patent: 5,616,599

Title:	Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
Abstract:	Compounds of the following formula (I) or the formula (I).sub.p : ##STR1## wherein R.sup.1 is alkyl or alkenyl; R.sup.2 and R.sup.3 are hydrogen, alkyl, alkenyl, cycloalkyl, aralkyl, aryl, or aryl fused to cycloalkyl; R.sup.4 is hydrogen, alkyl, alkanoyl, alkenoyl, arylcarbonyl, alkoxycarbonyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothienyl, tetrahydrofuryl, a group of formula --SiR.sup.a R.sup.b R.sup.c, in which R.sup.a, R.sup.b and R.sup.c are alkyl or aryl, alkoxymethyl, (alkoxyalkoxy)methyl, haloalkoxymethyl, aralkyl, aryl or alkanoyloxymethoxycarbonyl; R.sup.5 is carboxy or --CONR.sup.8 R.sup.9, wherein R.sup.8 and R.sup.9 hydrogens or alkyl, or R.sup.8 and R.sup.9 together form alkylene; R.sup.6 is hydrogen, alkyl, alkoxy or halogen; R.sup.7 is carboxy or tetrazol-5-yl; R.sub.p.sup.1 is hydrogen, alkyl, cycloalkyl or alkanoyl; R.sub.p.sup.2 is a single bond, alkylene or alkylidene; R.sub.p.sup.3 and R.sub.p.sup.4 are each hydrogen or alkyl; R.sub.p.sup.6 is carboxy or tetrazol-5-yl; and X.sub.p is oxygen or sulfur; and pharmaceutically acceptable salts and esters thereof. The compounds are AII receptor antagonists and thus have hypotensive activity and can be used for the treatment and prophylaxis of hypertension. The compounds may be prepared by reacting a biphenylmethyl compound with an imidazole compound.
Inventor(s):	Yanagisawa; Hiroaki (Tokyo, JP), Fujimoto; Koichi (Tokyo, JP), Amemiya; Yoshiya (Tokyo, JP), Shimoji; Yasuo (Tokyo, JP), Kanazaki; Takuro (Tokyo, JP), Koike; Hiroyuki (Tokyo, JP), Sada; Toshio (Tokyo, JP)
Assignee:	Sankyo Company, Limited (Tokyo, JP)
Application Number:	08/378,650
Patent Claims:	1. A compound of formula (I): ##STR24## wherein: R.sup.1 represents an alkyl group having from 2 to 5 carbon atoms or an alkenyl group having from 3 to 5 carbon atoms; R.sup.2 and R.sup.3 are independently selected from the group consisting of: alkyl groups having from 1 to 4 carbon atoms; R.sup.4 represents: a hydrogen atom; a methyl group; an ethyl group; or an alkanoyl group having from 1 to 5 carbon atoms; R.sup.5 represents a group of formula --COOR.sup.5a or a group of formula --CONR.sup.8 R.sup.9, R.sup.5a represents a hydrogen atom, an alkyl group having from 1 to 4 carbon atoms, a benzyl group, an alkanoyloxyalkyl group, in which the alkanoyl part has from 1 to 5 carbon atoms, and the alkyl part is a methyl or ethyl group, a cycloalkanoyloxyalkyl group, in which the cycloalkanoyl part has 6 or 7 carbon atoms, and the alkyl part is a methyl or ethyl group, an alkoxycarbonyloxyalkyl group, in which the alkoxy part has from 1 to 4 carbon atoms, and the alkyl part is a methyl or ethyl group, a cycloalkoxycarbonyloxyalkyl group, in which the cycloalkoxy part has 5 or 6 carbon atoms, and the alkyl part is a methyl or ethyl group, a (5-phenyl-2-oxo-1,3-dioxolen-4-yl)methyl group, a (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl group, a (5-ethyl-2-oxo-1,3dioxolen-4-yl)methyl group or a phthalidyl group; R.sup.8 and R.sup.9 are independently selected from the group consisting of hydrogen atoms, methyl groups, ethyl groups, methoxycarbonylmethyl groups, ethoxycarbonylmethyl groups and carboxymethyl groups; or R.sup.8 and R.sup.9 together represent a tetramethylene, pentamethylene, 1-carboxytetramethylene or 1-carboxypentamethylene group; R.sup.6 represents a hydrogen atom, a methyl group, a methoxy group or a fluorine atom or a chlorine atom at the 6-position of the benzene ring; R.sup.7 represents a carboxy group or a tetrazol-5-yl group at the 2-position of the benzene ring; the benzyl ring which bears the substituents represented by R.sup.6 and R.sup.7 is at the 4-position of the benzyl group to which it is attached; and pharmaceutically acceptable salts and esters thereof. 2. The compound of claim 1, wherein R.sup.5a represents a pivaloyloxymethyl, ethoxycarbonyloxymethyl, 1-(ethoxycarbonyloxy)ethyl, isopropoxycarbonyloxymethyl, (1-isopropoxycarbonyloxy)ethyl, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl or phthalidyl group. 3. The compound of claim 1, wherein: R.sup.1 represents an ethyl, propyl or butyl group; R.sup.2 and R.sup.3 are methyl groups; R.sup.4 represents a hydrogen atom or a methyl group; R.sup.5 represents a group of formula --COOR.sup.5a, in which R.sup.5a represents a hydrogen atom, a pivaloyloxymethyl group, an ethoxycarbonyloxymethyl group, a 1-(ethoxycarbonyloxy)ethyl group, an isopropoxycarbonyloxymethyl group, a 1-(isopropoxycarbonyloxy)ethyl group, a (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl group, or a phthalidyl group; and R.sup.6 represents a hydrogen atom. 4. The compound of claim 1, selected from the group consisting of 2-butyl-1-[(2'-carboxybiphenyl-4-yl)methyl]-4-(1-hydroxy-1-methylethyl)imi dazole-5-carboxylic acid and pharmaceutically acceptable salts thereof. 5. The compound of claim 1, selected from the group consisting of pivaloyloxymethyl 2-butyl-1-[(2'-carboxybiphenyl-4-yl)methyl]-4-(1-hydroxy-1-methylethyl)imi dazole-5-carboxylate and pharmaceutically acceptable salts thereof. 6. The compound of claim 1, selected from the group consisting of (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 2-butyl-1-[(2'-carboxybiphenyl-4-yl)methyl]-4-(1-hydroxy-1-methylethyl)imi dazole-5-carboxylate and pharmaceutically acceptable salts thereof. 7. The compound of claim 1, selected from the group consisting of 1-[(2'-carboxybiphenyl-4-yl)methyl]-4-(1-hydroxy-1-methylethyl)-2-propylim idazole-5-carboxylic acid and pharmaceutically acceptable salts thereof. 8. The compound of claim 1, selected from the group consisting of 1-[(2'-carboxybiphenyl-4-yl)methyl]-2-ethyl-4-(1-hydroxy-1-methylethyl)imi dazole-5-carboxylic acid and pharmaceutically acceptable salts thereof. 9. The compound of claim 1, selected from the group consisting of 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl} methylimidazole-5-carboxylic acid and pharmaceutically acceptable salts thereof. 10. The compound of claim 1, selected from the group consisting of 2-butyl-4-(1-hydroxy-1-methylethyl)-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}m ethylimidazole-5-carboxylic acid and pharmaceutically acceptable salts thereof. 11. The compound of claim 1, selected from the group consisting of pivaloyloxymethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl} -methylimidazole-5-carboxylate and pharmaceutically acceptable salts thereof. 12. The compound of claim 1, selected from the group consisting of pivaloyloxymethyl 2-butyl-4-(1-hydroxy-1-methylethyl)-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}- methylimidazole-5-carboxylate and pharmaceutically acceptable salts thereof. 13. The compound of claim 1, selected from the group consisting of (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl} methylimidazole-5-carboxylate and pharmaceutically acceptable salts thereof. 14. The compound of claim 1, selected from the group consisting of (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 2-butyl-4-(1-hydroxy-1-methylethyl)-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}m ethylimidazole-5-carboxylate and pharmaceutically acceptable salts thereof. 15. The compound of claim 1, selected from the group consisting of ethoxycarbonyloxymethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl} methylimidazole-5-carboxylate and pharmaceutically acceptable salts thereof. 16. The compound of claim 1, selected from the group consisting of isopropoxycarbonyloxymethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl} methylimidazole-5-carboxylate and pharmaceutically acceptable salts thereof. 17. The compound of claim 1, selected from the group consisting of 1-(ethoxycarbonyloxy)ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl} methylimidazole-5-carboxylate and pharmaceutically acceptable salts thereof. 18. The compound of claim 1, selected from the group consisting of 1-(isopropoxycarbonyloxy)ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl} methylimidazole-5-carboxylate and pharmaceutically acceptable salts thereof. 19. The compound of claim 1, selected from the group consisting of pivaloyloxymethyl 2-ethyl-4-(1-hydroxy-1-methylethyl)-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}- methylimidazole-5-carboxylate and pharmaceutically acceptable salts thereof. 20. The compound of claim 1, selected from the group consisting of (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 2-ethyl-4-(1-hydroxy-1-methylethyl)-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}m ethylimidazole-5-carboxylate and pharmaceutically acceptable salts thereof. 21. The compound of claim 1, selected from the group consisting of pivaloyloxymethyl 1-[(2'-carboxybiphenyl-4-yl)methyl]-4-(1-hydroxy-1-methylethyl)-2-propylim idazole-5-carboxylate and pharmaceutically acceptable salts thereof. 22. The compound of claim 1, selected from the group consisting of (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 1-[(2'-carboxybiphenyl-4-yl)methyl]-4-(1-hydroxy-1-methylethyl)-2-propylim idazole-5-carboxylate and pharmaceutically acceptable salts thereof. 23. The compound of claim 1, selected from the group consisting of phthalidyl 1-[(2'-carboxybiphenyl-4-yl)methyl]-4-(1-hydroxy-1-methylethyl)-2-propylim idazole-5-carboxylate and pharmaceutically acceptable salts thereof. 24. A pharmaceutical composition for the treatment or prophylaxis of hypertension, which comprises an effective amount of an anti-hypertensive agent in admixture with a pharmaceutically acceptable carrier or diluent, wherein the anti-hypertensive agent is selected from the group consisting of compounds of formula (I) and pharmaceutically acceptable salts thereof, as claimed in claim 1. 25. The composition of claim 24, wherein said anti-hypertensive agent is selected from the group consisting of: 2-butyl-1-[(2'-carboxybiphenyl-4-yl)methyl]-4-(1-hydroxy-1-methylethyl)imid azole-5-carboxylic acid; pivaloyloxymethyl 2-butyl-1-[(2'-carboxybiphenyl-4-yl)methyl]-4-(1-hydroxy-1-methylethyl)imi dazole-5-carboxylate; (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 2-butyl-1-[(2'-carboxybiphenyl-4-yl)methyl]-4-(1-hydroxy-1-methylethyl)imi dazole-5-carboxylate; 1-[(2'-carboxybiphenyl-4-yl)methyl]-4-(1-hydroxy-1-methylethyl)-2-propylimi dazole-5-carboxylic acid; 1-[(2'-carboxybiphenyl-4-yl)methyl]-2-ethyl-4-(1-hydroxy-1-methylethyl)imid azole-5-carboxylic acid; 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}m ethylimidazole-5-carboxylic acid; 2-butyl-4-(1-hydroxy-1-methylethyl)-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}me thylimidazole-5-carboxylic acid; pivaloyloxymethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl} methylimidazole-5-carboxylate; pivaloyloxymethyl 2-butyl-4-(1-hydroxy-1-methylethyl)-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}m ethylimidazole-5-carboxylate; (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}m ethylimidazole-5-carboxylate; (5-methyl-2-oxo-1,3-idoxolen-4-yl)methyl 2-butyl-4-(1-hydroxy-1-methylethyl)-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}m ethylimidazole-5-carboxylate; ethoxycarbonyloxymethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl} methylimidazole-5-carboxylate; isopropoxycarbonyloxymethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl} methylimidazole-5-carboxylate; 1-(ethoxycarbonyloxy)ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl} methylimidazole-5-carboxylate; 1-(isopropoxycarbonyloxy)ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl} methylimidazole-5-carboxylate; pivaloyloxymethyl 2-ethyl-4-(1-hydroxy-1-methylethyl)-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}m ethylimidazole-5-carboxylate; (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 2-ethyl-4-(-1-hydroxy-1-methylethyl)-1-{4-[2-(tetrazol-5-yl-phenyl]phenyl} methylimidazole-5-carboxylate; pivaloyloxymethyl 1-[(2'-carboxybiphenyl-4-yl)methyl]-4-(1-hydroxy-1-methylethyl)-2-propylim idazole-5-carboxylate; (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 1-[(2'-carboxybiphenyl-4-yl)methyl]-4-(1-hydroxy-1-methylethyl)-2-propylim idazole-5-carboxylate; phthalidyl 1-[(2'-carboxybiphenyl-4-yl)methyl]-4-(1-hydroxy-1-methylethyl)-2-propylim idazole-5-carboxylate; and pharmaceutically acceptable salts thereof. 26. A method for the treatment of prophylaxis of hypertension in a mammal which comprises administering an effective amount of an anti-hypertensive agent to said mammal, wherein the anti-hypertensive agent is selected from the group consisting of compounds of formula (I) and pharmaceutically acceptable salts thereof, as claimed in claim 1. 27. The method of claim 26, wherein said anti-hypertensive agent is selected from the group consisting of: 2-butyl-1-[(2'-carboxybiphenyl-4-yl)methyl]-4-(1-hydroxy-1-methylethyl)imid azole-5-carboxylic acid; pivaloyloxymethyl 2-butyl-1-[(2'-carboxybiphenyl-4-yl)methyl]-4-(1-hydroxy-1-methylethyl)imi dazole-5-carboxylate; (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 2-butyl-1-[(2'-carboxybiphenyl-4-yl)methyl]-4-(1-hydroxy-1-methylethyl)imi dazole-5-carboxylate; 1-[(2'-carboxybiphenyl-4-yl)methyl]-4-(1-hydroxy-1-methylethyl)-2-propylimi dazole-5-carboxylic acid; 1-[(2'-carboxybiphenyl-4-yl)methyl]-2-ethyl-4-(1-hydroxy-1-methylethyl)imid azole-5-carboxylic acid; 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}m ethylimidazole-5-carboxylic acid; 2-butyl-4-(1-hydroxy-1-methylethyl)-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}me thylimidazole-5-carboxylic acid; pivaloyloxymethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl} methylimidazole-5-carboxylate; pivaloyloxymethyl 2-butyl-4-(1-hydroxy-1-methylethyl)-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}m ethylimidazole-5-carboxylate; (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl} methylimidazole-5-carboxylate; (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 2-butyl-4-(1-hydroxy-1-methylethyl)-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}m ethylimidazole-5-carboxylate; ethoxycarbonyloxymethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl} methylimidazole-5-carboxylate; isopropoxycarbonyloxymethtyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl} methylimidazole-5-carboxylate; 1-(ethoxycarbonyloxy)ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl} methylimidazole-5-carboxylate; 1-(isopropoxycarbonyloxy)ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl} methylimidazole-5-carboxylate; pivaloyloxymethyl 2-ethyl-4-(1-hydroxy-1-methylethyl)-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}m ethylimidazole-5-carboxylate; (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 2-ethyl-4-(1-hydroxy-1-methylethyl)-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}m ethylimidazole-5-carboxylate; pivaloyloxymethyl 1-[(2'-carboxybiphenyl-4-yl)methyl]-4-(1-hydroxy-1-methylethyl)-2-propylim idazole-5-carboxylate; (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 1-[(2'-carboxybiphenyl-4-yl)methyl]-4-(1-hydroxy-1-methylethyl)-2-propylim idazole-5-carboxylate; phthalidyl 1-[(2'-carboxybiphenyl-4-yl)methyl]-4-(1-hydroxy-1-methylethyl)-2-propylim idazole-5-carboxylate; and pharmaceutically acceptable salts thereof. 28. The compound of claim 1, wherein R.sup.2 and R.sup.3 are both methyl groups. 29. The compound of claim 1, wherein both of R.sup.2 and R.sup.3 are ethyl groups. 30. The compound of claim 1, wherein one of R.sup.2 and R.sup.3 is a methyl group and the other of R.sup.2 and R.sup.3 is an ethyl group. 31. The compound of claim 1, wherein R.sup.5 is ##STR25## 32. The composition of claim 21, wherein R.sup.2 and R.sup.3 are both methyl groups. 33. The method of claim 26, wherein R.sup.2 and R.sup.3 are both methyl groups. 34. A compound of formula (I): ##STR26## wherein: R.sup.1 represents an alkyl group having from 1 to 6 carbon atoms or an alkenyl group having from 3 to 6 carbon atoms; R.sup.2 and R.sup.3 are independently alkyl groups having from 1 to 6 carbon atoms; R.sup.4 represents: a hydrogen atom; an alkyl group having from 1 to 6 carbon atoms; an alkanoyl group having from 1 to 6 carbon atoms; a substituted alkanoyl group having from 2 to 6 carbon atoms and substituted by at least one substituent selected from the group consisting of halogen atoms and alkoxy groups having from 1 to 6 carbon atoms; an alkenoyl group having from 3 to 6 carbon atoms; an arylcarbonyl group in which the aryl part is as defined below; an alkoxycarbonyl group in which the alkyl part has from 1 to 6 carbon atoms; a tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothienyl or tetrahydrofuryl group; a substituted tetrahydropyranyl, tetrahydrofuryl group which is substituted by at least one substituent selected from the group consisting of halogen atoms and alkoxy groups having from 1 to 6 carbon atoms; alkoxymethyl groups in which the alkoxy part has from 1 to 6 carbon atoms; (alkoxyalkoxy)methyl groups in which each alkoxy part has from 1 to 6 carbon atoms; haloalkoxymethyl groups in which the alkoxy part has from 1 to 6 carbon atoms; aralkyl groups, in which an alkyl group having from 1 to 6 carbon atoms is substituted by at least one aryl group, as defined below; or alkanoyloxymethoxycarbonyl groups in which the alkanoyl part has from 1 to 6 carbon atoms; R.sup.5 represents a carboxy group or a group of formula --CONR.sup.8 R.sup.9, wherein R.sup.8 and R.sup.9 are independently selected from the group consisting of hydrogen atoms, unsubstituted alkyl groups having from 1 to 6 carbon atoms, and substituted alkyl groups which have from 1 to 6 carbon atoms and which are substituted by at least one substituent selected from the group consisting of substituents (a), defined below, or R.sup.8 and R.sup.9 together represent an unsubstituted alkylene group having from 2 to 6 carbon atoms or a substituted alkylene group which has from 2 to 6 carbon atoms and which is substituted by at least one substituent selected from the group consisting of carboxy groups and alkoxycarbonyl groups in which the alkyl part has from 1 to 6 carbon atoms; R.sup.6 represents a hydrogen atom, an alkyl group having from 1 to 6 carbon atoms, an alkoxy group having from 1 to 6 carbon atoms or a halogen atom; R.sup.7 represents a carboxy group or a tetrazol-5-yl group; said substituents (a) are selected from the group consisting of: aryl groups as defined below; heterocyclic groups having 5 or 6 ring atoms, of which from 1 to 4 are hetero-atoms selected from the group consisting of nitrogen, oxygen and sulfur atoms; halogen atoms; hydroxy groups; alkoxy groups having from 1 to 6 carbon atoms; carboxy groups alkoxycarbonyl groups in which the alkyl part has from 1 to 6 carbon atoms; amino groups; and acylamino groups, in which the acyl part is an alkanoyl group having from 1 to 6 carbon atoms or an arylcarbonyl group, in which the aryl part is as defined below; said aryl groups are aromatic carbocyclic groups which have from 6 to 14 ring atoms and which are unsubstituted or are substituted by at least one substituent selected from the group consisting of substituents (b), defined below; and said substituents (b) are selected from the group consisting of nitro groups, cyano groups, halogen atoms, unsubstituted carbocyclic aryl groups having from 6 to 10 ring atoms, alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, carboxy groups, alkoxycarbonyl groups in which the alkoxy part has from 1 to 6 carbon atoms and alkylenedioxy and alkylidene-dioxy groups having from 1 to 3 carbon atoms; and pharmaceutically acceptable salts thereof. 35. The compound of claim 1, wherein R.sup.2 and R.sup.3 are methyl and R.sup.4 is hydrogen. 36. The compound of claim 1, wherein said R.sup.5 is the group of the formula --COOR.sup.5a. 37. The composition of claim 24, wherein said R.sup.5 is the group of the formula --COOR.sup.5a. 38. The method of claim 26, wherein said R.sup.5 is the group of the formula --COOR.sup.5a. 39. The compound of claim 1, wherein: R.sup.1 represents an alkyl group having from 2 to 5 carbon atoms; and R.sup.5a represents a hydrogen atom, a methyl, ethyl or benzyl group, an alkanoyloxymethyl group, in which the alkanoyl part has from 1 to 5 carbon atoms, a 1-(alkanoyloxy)ethyl group, in which the alkanoyl part has from 1 to 5 carbon atoms, an alkoxycarbonyloxymethyl group, in which the alkoxy part has from 1 to 4 carbon atoms, a 1-(alkoxycarbonyloxy)ethyl group, in which the alkoxy part has from 1 to 4 carbon atoms, a (5-phenyl-2-oxo-1,3-dioxolen-4-yl)methyl group, a (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl group or a phthalidyl group. 40. The compound of claim 39, wherein R.sup.2 and R.sup.3 are both methyl groups. 41. The composition of claim 24, wherein: R.sup.1 represents an alkyl group having from 2 to 5 carbon atoms; and R.sup.5a represents a hydrogen atom, a methyl, ethyl or benzyl group, an alkanoyloxymethyl group, in which the alkanoyl part has from 1 to 5 carbon atoms, a 1-(alkanoyloxy)ethyl group, in which the alkanoyl part has from 1 to 5 carbon atoms, an alkoxycarbonyloxymethyl group, in which the alkoxy part has from 1 to 4 carbon atoms, a 1-(alkoxycarbonyloxy)ethyl group, in which the alkoxy part has from 1 to 4 carbon atoms, a (5-phenyl-2-oxo-1,3-dioxolen-4-yl)methyl group, a (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl group or a phthalidyl group. 42. The method of claim 26, wherein: R.sup.1 represents an alkyl group having from 2 to 5 carbon atoms; and R.sup.5a represents a hydrogen atom, a methyl, ethyl or benzyl group, an alkanoyloxymethyl group, in which the alkanoyl part has from 1 to 5 carbon atoms, a 1-(alkanoyloxy)ethyl group, in which the alkanoyl part has from 1 to 5 carbon atoms, an alkoxycarbonyloxymethyl group, in which the alkoxy part has from 1 to 4 carbon atoms, a 1-(alkoxycarbonyloxy)ethyl group, in which the alkoxy part has from 1 to 4 carbon atoms, a (5-phenyl-2-oxo-1,3-dioxolen-4-yl)methyl group, a (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl group or a phthalidyl group.